sabatolimab (MBG453) - Novartis
spartalizumab (PDR001) - Novartis
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM (clinicaltrials.gov) - Oct 8, 2026 - P1 | N=16 | Completed | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting ➔ Completed 
Trial completion • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • MGMT
http://clinicaltrials.gov/ct2/show/NCT03961971
 
Oct 8, 2026
 
Prev Next